FOXO TECHNOLOGIES INC. (FOXO): Entry into a Material Definitive Agreement
FOXO TECHNOLOGIES INC. (FOXO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 FOXO TECHNOLOGIES INC. ANNOUNCES AGREEMENTS TO ACQUIRE PREFERRED STOCK CARRYING MAJORITY VOTING POWER IN LUDWIG ENTERPRISES, INC. WEST PALM BEACH, FL, October 29, 2026 (GLOBE NEWSWIRE) — FOXO Technologies Inc . (OTC: FOXO) (“FOXO” or the “Company”) today announced th
- Role
- acquirer
- Counterparty
- Ludwig Enterprises, Inc.
- Seller
- Thomas E. Terwilliger, individually, whose revocable trust is one of the selling preferred stockholders
- Consideration
- stock
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The announced agreements could provide FOXO with new mRNA diagnostic technology but hinge on regulatory and financing milestones.
Market read
Primary disclosure of a pending acquisition; modest impact expected pending Nasdaq listing and financing.
What to watch
Financing terms and the valuation of Ludwig's preferred stock are undisclosed, adding risk.
Background
FOXO Technologies Inc. is an OTC‑listed health‑care company with subsidiaries in hospitals, behavioral health, biospecimen sourcing, and biotech.
Ticker impact
FOXO filed an 8‑K announcing stock purchase agreements to acquire preferred shares of Ludwig Enterprises, a material definitive agreement.
possible upward pressure if Nasdaq listing and financing succeed, otherwise limited impact
The deal is pending and contingent on financing and Nasdaq approval, creating uncertainty around immediate price effect.
Market effects
May signal increased M&A activity in the niche mRNA diagnostic sector.
Limited to U.S. OTC market; no broader regional effect.
Low global relevance beyond niche biotech investors.
Counterpoint
If Nasdaq listing fails, the acquisition could collapse, leading to a sell‑off in FOXO.
Key entities
- companyFOXO Technologies Inc.
OTC‑listed health‑care firm filing the 8‑K.
- companyLudwig Enterprises, Inc.
Nevada biotech developing mRNA biomarker platform.



